FDA Approves Orca Bio's Tregzi, a Cell Therapy for Preventing Graft-versus-Host Disease in Blood Cancers
First Regulatory Approval for a Regulatory T-cell Therapy
On June 30, 2026, the U.S. Food and Drug Administration (FDA) granted marketing authorization for Tregzi (Orca-T), Orca Bio's novel cell therapy designed to prevent chronic graft-versus-host disease (cGVHD) and improve progression-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Tregzi represents a significant advancement in immune cell therapy, addressing a critical unmet need for effective prophylactic treatments for graft-versus-host disease, a major complication of allogeneic stem cell transplantation. This approval is expected to dramatically improve post-transplant outcomes and long-term survival for patients.
Demonstrated Superior Efficacy Based on Phase 3 Clinical Data
The approval is based on data from the Precision-T study (NCT05316701), a randomized, controlled Phase 3 trial involving a total of 187 patients comparing Tregzi to standard treatment. The study demonstrated that patients receiving Tregzi achieved a one-year chronic graft-versus-host disease-free survival (cGVHD-free survival) rate of 78%, compared to 38% in the control group, representing a more than two-fold improvement in outcomes. Furthermore, the cumulative incidence of moderate-to-severe cGVHD at 12 months post-transplant was 12.6% in the Tregzi group, compared to 44.0% in the control group, highlighting the therapy's superior ability to manage adverse events.
Precision Separation and Recombination of Three Cell Populations
Tregzi is not simply a cell transplant; it employs a sophisticated platform technology that precisely separates and recombines three cell populations from the donor's blood: hematopoietic stem and progenitor cells (HSPCs), highly purified regulatory T cells (Tregs), and conventional T cells (Tcons). These cells are then administered sequentially in an optimized ratio. Regulatory T cells act as a safety mechanism, controlling excessive immune attacks by donor cells against the recipient's normal tissues, while conventional T cells maintain graft-versus-leukemia (GVL) activity to eliminate residual cancer cells, thereby enhancing therapeutic efficacy. The commercial success of this immune control platform marks a technological innovation that expands the focus of cell therapy development from cell depletion to immune suppression and physiological regulation.
Capital Raising and Manufacturing Expansion to Accelerate Commercialization
The global market for graft-versus-host disease (GVHD) prevention and treatment is projected to grow rapidly, reaching approximately $3.65 billion to $7.3 billion (approximately 5 to 10 trillion KRW) by 2033-2035. Following FDA approval, Orca Bio, a privately held biotechnology company, has secured a total of $250 million (approximately 340 billion KRW) in equity financing, including a Series F round completed in late 2025, and a $100 million credit facility to accelerate commercialization. The company plans to leverage these resources to expand its manufacturing capacity on both the U.S. East and West Coasts, enabling rapid and efficient delivery of the therapy to transplant centers nationwide shortly after launch.
The successful Phase 3 trial (Precision-T) and subsequent FDA approval of Tregzi signal the emergence of a new leader in the market for preventing refractory chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation. Data demonstrating a more than two-fold improvement in one-year chronic graft-versus-host disease-free survival (cGVHD-free survival) compared to existing prophylactic standard therapies (from 38% to 78%) represent a significant clinical advance. This is poised to disrupt the existing competitive landscape, challenging established prophylactic agents like Orencia and approved therapies like Jakafi, and will likely accelerate the reshaping of the global GVHD market, projected to reach up to $7.3 billion by 2033. In the long term, the validation of a unique platform that maintains both immune suppression and graft-versus-leukemia (GVL) efficacy will serve as a valuation driver for the broader field of allogeneic cell therapies. With $250 million in funding secured, Orca Bio is well-positioned to rapidly deploy a nationwide supply chain in the U.S., significantly shortening the timeline for realizing near-term revenues.